The big data challenge-and how polypharmacology supports the translation from pre-clinical research into clinical use against neurodegenerative diseases and beyond  

作　　者：Sven Marcel Stefan Muhammad Rafehi 

机构地区：[1]Drug Development and Chemical Biology,Lübeck Institute of Experimental Dermatology(LIED),University of Lübeck and University Medical Center Schleswig-Holstein,Lübeck,Germany [2]Department of Pathology,Section of Neuropathology,Translational Neurodegeneration Research and Neuropathology Lab,University of Oslo and Oslo University Hospital,Oslo,Norway [3]School of Medical Sciences,Faculty of Medicine and Health,University of Sydney,Sydney,NSW,Australia [4]Institute of Clinical Pharmacology,University Medical Center Göttingen,Göttingen,Germany [5]Department of Medical Education,Augsburg University Medicine,Augsburg,Germany

出　　处：《Neural Regeneration Research》2024年第8期1647-1648,共2页中国神经再生研究(英文版)

基　　金：supported by the Walter Benjamin and Research Grant Programs of the German Research Foundation(Deutsche Forschungsgemeinschaft,DFG,Germany,#446812474,#504079349[PANABC])(to SMS),the DFG(#437446827);the Research Program of the University Medical Center Gottingen(to MR)。

摘　　要：Introductory comments:The identification and validation of disease-modifying proteins are fundamental aspects in drug development.However,the m ultifactority of n eurodegen era tive diseases poses a real challenge for targeted therapies.Furthermore,the behavior of individually(over-)expressed to rget proteins in vitro is likely to differ from their actual functional behavior when embedded in cascades and pathways in vivo.

关 键 词：TRANSLATION BEYOND LIKELY 

分 类 号：R741[医药卫生—神经病学与精神病学]